February 1, 2011
Otsuka Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Otsuka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
Tokyo, Japan, February 1, 2011 -- Otsuka Pharmaceutical Co., Ltd. today announced the initiation of the phase II clinical trial of OCV-101* for pancreatic cancer in Japan. OCV-101 is an angiogenesis inhibitor which has been co-developed by OncoTherapy Science, Inc. and Otsuka Pharmaceutical.
- * OCV-101: Formally named OTS11101. The development code was changed from the start of this trial.
OCV-101 X is a therapeutic cancer vaccine targeting the endothelial cells of new blood vessels feeding tumors. The phase II clinical trial will evaluate the efficacy and safety of OCV-101 for the treatment of patients with unresectable advanced pancreatic cancer and recurrent pancreatic cancer. This trial will be conducted in eight medical institutions in Japan.
Based on its corporate philosophy of 'Otsuka-people creating new products for better health worldwide,' Otsuka Pharmaceutical is dedicated to contributing to the health of people around the world.
Information in this news release was current as of the original release date.